EyePoint Pharmaceuticals: Q1 Earnings Insights

 

Shares of EyePoint Pharmaceuticals EYPT moved higher by 2.0% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 233.33% over the past year to ($0.50), which missed the estimate of ($0.46).

Revenue of $7,323,000 rose by 191.87% from the same period last year, which missed the estimate of $7,930,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 05, 2021

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/ry4nzci3

Recent Stock Performance

52-week high: $15.06

52-week low: $0.35

Price action over last quarter: Up 12.50%

Company Description

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!